Notice of MIGENIX General Meeting of Shareholders

MGIFF), a clinical-stage developer of drugs for infectious diseases, advises
that the directors of MIGENIX Inc. have called a general meeting of
shareholders (the "Meeting") to be held at 2:00 p.m. (Vancouver time) on
October 31, 2008, at 102 - 2389 Health Sciences Mall, Vancouver, British
Columbia. Further details with respect to the Meeting will be provided in an
Information Circular to be prepared by MIGENIX and sent to shareholders,
together with a Form of Proxy, Notice of Meeting and other relevant Meeting

    About MIGENIX

    MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's programs include drug candidates for:
the prevention of catheter-related infections (Phase III), the treatment of
dermatological diseases (end of Phase II), the treatment of chronic hepatitis
C infections (Phase II and preclinical), the treatment of serious gram
positive bacterial infections (preclinical) and the treatment of hepatitis B
infections (preclinical). MIGENIX is headquartered in Vancouver, British
Columbia, Canada with US operations in San Diego, California. Additional
information can be found at

    "Jim DeMesa"
    James M. DeMesa, M.D.
    President & CEO

For further information:

For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233,; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890